Synopsis
Synopsis
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Apo-chlorpropamide
2. Clorpropamid
3. Diabinese
4. Glucamide
5. Insogen
6. Meldian
1. 94-20-2
2. Chloropropamide
3. Diabinese
4. Glucamide
5. Meldian
6. Chlorpropamid
7. Diabenese
8. Chlorodiabina
9. Chloronase
10. Diabeneza
11. Diabetoral
12. Adiaben
13. Catanil
14. Diabaril
15. Dynalase
16. Insulase
17. Melitase
18. Diabechlor
19. Diabenal
20. Mellinese
21. Millinese
22. Asucrol
23. Glisema
24. Oradian
25. Diabet-pages
26. Diamel Ex
27. 1-(4-chlorophenylsulfonyl)-3-propylurea
28. 4-chloro-n-(propylcarbamoyl)benzenesulfonamide
29. Clorpropamide
30. Diabexan
31. Prodiaben
32. Chlorpropamidum
33. Clorpropamida
34. 1-(p-chlorobenzenesulfonyl)-3-propylurea
35. 1-(4-chlorophenyl)sulfonyl-3-propylurea
36. 1-propyl-3-(p-chlorobenzenesulfonyl)urea
37. N-(4-chlorophenylsulfonyl)-n'-propylurea
38. N-(p-chlorobenzenesulfonyl)-n'-propylurea
39. N-propyl-n'-(p-chlorobenzenesulfonyl)urea
40. 4-chloro-n-[(propylamino)carbonyl]benzenesulfonamide
41. 1-(p-chlorophenylsulfonyl)-3-propylurea
42. 1-p-chlorophenyl-3-(propylsulfonyl)urea
43. Nci-c01752
44. 4-chloro-n-((propylamino)carbonyl)benzenesulfonamide
45. N-propyl-n'-p-chlorphenylsulfonylcarbamide
46. 1-((p-chlorophenyl)sulfonyl)-3-propylurea
47. N-propyl-n'-p-chlorophenylsulfonylcarbamide
48. 1-[(4-chlorobenzene)sulfonyl]-3-propylurea
49. P 607
50. Nsc 44634
51. Benzenesulfonamide, 4-chloro-n-((propylamino)carbonyl)-
52. U-9818
53. 4-chloro-4-((propylamino)carbonyl)benzenesulfonamide
54. Benzenesulfonamide, 4-chloro-n-[(propylamino)carbonyl]-
55. Clorpropamid
56. Mfcd00079004
57. Nsc-44634
58. Wtm2c3il2x
59. Chembl498
60. Nsc-626720
61. Mls000028395
62. Chebi:3650
63. Bioglumin
64. Insogen
65. Urea, 1-((p-chlorophenyl)sulfonyl)-3-propyl-
66. Nsc626720
67. Cas-94-20-2
68. Ncgc00015216-11
69. Chlorporpamide
70. Smr000058364
71. Clorpropamide [dcit]
72. Dsstox_cid_322
73. Chlorpropamide, Alpha-form
74. Clorpropamide [italian]
75. Urea, 1-[(p-chlorophenyl)sulfonyl]-3-propyl-
76. Chlorpropamide, Epsilon-form
77. Dsstox_rid_75512
78. Dsstox_gsid_20322
79. Chlorpropamide, Epsilon`-form
80. Chlorpropamidum [inn-latin]
81. Clorpropamida [inn-spanish]
82. Diabinese (tn)
83. Ccris 155
84. 1-(p-chlorobenzensulfonyl)-3-propylurea
85. Hsdb 2051
86. 4-chloro-n-(propylaminocarbonyl)benzenesulfonamide
87. Sr-01000000060
88. 4-chloro-n-((propylaminocarbonyl)benzenesulfonamide
89. Einecs 202-314-5
90. Unii-wtm2c3il2x
91. U-3818
92. Nsc 626720
93. Brn 2218363
94. Urea, 1-((p-chloropenyl)sulfonyl)-3-propyl-
95. Prestwick_684
96. Chlorpropamide [usp:inn:ban:jan]
97. Chlorpropamide B.p.
98. Chlorpropamide-[d4]
99. Spectrum_000144
100. 1-(4-chlorobenzenesulfonyl)-3-propylurea
101. 1-(4-chlorophenyl)sulfonyl-3-propyl-urea
102. Opera_id_359
103. Adenylosuccinicacid
104. Prestwick0_000323
105. Prestwick1_000323
106. Prestwick2_000323
107. Prestwick3_000323
108. Spectrum2_000089
109. Spectrum3_000347
110. Spectrum4_000284
111. Spectrum5_000719
112. Wln: Gr Dswmvm3
113. Lopac-c-1290
114. Chlorpropamide, Delta-form
115. 1-(4-chloro-benzenesulfonyl)-3-n-propyl-urea
116. C 1290
117. Chlorpropamide [mi]
118. Chlorpropamide [inn]
119. Chlorpropamide [jan]
120. Lopac0_000229
121. Schembl23947
122. Bspbio_000325
123. Bspbio_002013
124. Chlorpropamide [hsdb]
125. Kbiogr_000808
126. Kbiogr_002273
127. Kbioss_000624
128. Kbioss_002274
129. Mls001148665
130. Chlorpropamide [vandf]
131. Divk1c_000513
132. Spectrum1500185
133. Spbio_000018
134. Spbio_002246
135. Chlorpropamide [mart.]
136. Bpbio1_000359
137. Gtpl6801
138. Chlorpropamide [usp-rs]
139. Chlorpropamide [who-dd]
140. Dtxsid9020322
141. Hms501j15
142. Kbio1_000513
143. Kbio2_000624
144. Kbio2_002273
145. Kbio2_003192
146. Kbio2_004841
147. Kbio2_005760
148. Kbio2_007409
149. Kbio3_001233
150. Kbio3_002753
151. Chlorpropamide (jp17/usp/inn)
152. Cmap_000007
153. Ninds_000513
154. Hms1569a07
155. Hms1920m05
156. Hms2091e08
157. Hms2096a07
158. Hms2233l19
159. Hms3259a17
160. Hms3260n19
161. Hms3373d09
162. Hms3428c03
163. Hms3652l03
164. Hms3713a07
165. Pharmakon1600-01500185
166. Bcp09162
167. Hy-b1429
168. Nsc44634
169. Zinc1530599
170. Chlorpropamide [ep Impurity]
171. Chlorpropamide [orange Book]
172. Tox21_110102
173. Tox21_201391
174. Tox21_302789
175. Tox21_500229
176. Ac8695
177. Bdbm50344965
178. Ccg-38905
179. Nsc756690
180. Nsc813219
181. S4166
182. Stk857458
183. Chlorpropamide [usp Monograph]
184. Akos001482739
185. Tox21_110102_1
186. Cs-4917
187. Db00672
188. Ks-5316
189. Lp00229
190. Nc00503
191. Nsc-756690
192. Nsc-813219
193. Sdccgsbi-0050217.p005
194. Idi1_000513
195. Mrf-0000539
196. Ncgc00015216-01
197. Ncgc00015216-02
198. Ncgc00015216-03
199. Ncgc00015216-04
200. Ncgc00015216-05
201. Ncgc00015216-06
202. Ncgc00015216-07
203. Ncgc00015216-08
204. Ncgc00015216-09
205. Ncgc00015216-10
206. Ncgc00015216-12
207. Ncgc00015216-13
208. Ncgc00015216-14
209. Ncgc00015216-17
210. Ncgc00015216-18
211. Ncgc00015216-23
212. Ncgc00021451-03
213. Ncgc00021451-04
214. Ncgc00021451-05
215. Ncgc00021451-06
216. Ncgc00021451-07
217. Ncgc00021451-08
218. Ncgc00256414-01
219. Ncgc00258942-01
220. Ncgc00260914-01
221. Sy052508
222. Sbi-0050217.p004
223. Ab00051944
224. C1220
225. Chlorpropamide, Analytical Standard, >=97%
226. Eu-0100229
227. P-607
228. Sw196839-3
229. A16447
230. D00271
231. Urea, 1-propyl-3-(p-chloro-benzenesulfonyl)-
232. Ab00051944_16
233. Ab00051944_17
234. Q1075324
235. Sr-01000000060-2
236. Sr-01000000060-4
237. Sr-01000000060-6
238. W-100205
239. 4-chloro-n-[(propylamino)-carbonyl]benzenesulfonamide
240. Brd-k97746869-001-05-6
241. Brd-k97746869-001-15-5
242. 1-chloro-4-(([(propylamino)carbonyl]amino)sulfonyl)benzene #
243. Chlorpropamide, European Pharmacopoeia (ep) Reference Standard
244. Chlorpropamide, United States Pharmacopeia (usp) Reference Standard
245. Chlorpropamide, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 276.74 g/mol |
|---|---|
| Molecular Formula | C10H13ClN2O3S |
| XLogP3 | 2.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 276.0335411 g/mol |
| Monoisotopic Mass | 276.0335411 g/mol |
| Topological Polar Surface Area | 83.6 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 345 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Chlorpropamide |
| PubMed Health | Chlorpropamide (By mouth) |
| Drug Classes | Hypoglycemic |
| Drug Label | Chlorpropamide is an oral blood-glucose-lowering drug of the sulfonylurea class. Chlorpropamide, USP is a white, crystalline powder, that has a slight odor. It is practically insoluble in water, but is soluble in alcohol. Chemically, it is 4-chloro-N... |
| Active Ingredient | Chlorpropamide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 100mg |
| Market Status | Prescription |
| Company | Ani Pharms; Mylan |
| 2 of 4 | |
|---|---|
| Drug Name | Diabinese |
| PubMed Health | Chlorpropamide (By mouth) |
| Drug Classes | Hypoglycemic |
| Active Ingredient | Chlorpropamide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 100mg |
| Market Status | Prescription |
| Company | Pfizer |
| 3 of 4 | |
|---|---|
| Drug Name | Chlorpropamide |
| PubMed Health | Chlorpropamide (By mouth) |
| Drug Classes | Hypoglycemic |
| Drug Label | Chlorpropamide is an oral blood-glucose-lowering drug of the sulfonylurea class. Chlorpropamide, USP is a white, crystalline powder, that has a slight odor. It is practically insoluble in water, but is soluble in alcohol. Chemically, it is 4-chloro-N... |
| Active Ingredient | Chlorpropamide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 100mg |
| Market Status | Prescription |
| Company | Ani Pharms; Mylan |
| 4 of 4 | |
|---|---|
| Drug Name | Diabinese |
| PubMed Health | Chlorpropamide (By mouth) |
| Drug Classes | Hypoglycemic |
| Active Ingredient | Chlorpropamide |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 250mg; 100mg |
| Market Status | Prescription |
| Company | Pfizer |
Hypoglycemic Agents
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Sulfonylureas are used to control hyperglycemia in NIDDM pt who cannot achieve appropriate control with changes in diet alone. /Sulfonylurea/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1509
...EFFECTIVE IN MATURITY-ONSET DIABETIC PT IN WHOM PANCREAS RETAINS CAPACITY TO SECRETE INSULIN. /SULFONYLUREAS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1520
MEDICATION (VET): IN DIABETES MELLITUS IN DOGS.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 110
For more Therapeutic Uses (Complete) data for CHLORPROPAMIDE (8 total), please visit the HSDB record page.
...STUDIES...INDICATE INCR INCIDENCE OF...DIFFICULTIES IN PT TAKING ORAL HYPOGLYCEMIC DRUG. ...VENTRICULAR TACHYCARDIA &...FIBRILLATION WERE NOTED...USUALLY DURING EARLY STAGES OF MYOCARDIAL INFARCTION... /SULFONYLUREA/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1522
SULFONYLUREAS SHOULD BE ADMINISTERED WITH CAUTION TO PT WITH EITHER RENAL OR HEPATIC INSUFFICIENCY /SULFONYLUREAS/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1509
VET: AVOID USE IN PREGNANT ANIMALS.
Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 110
VET: /SULFONYLUREA SUBSTANCES/...HAVE BEEN OF LITTLE VALUE IN CANINE DIABETES TREATMENT. ONLY MILDEST CASES HAVE RESPONDED AT ALL. /HYPOGLYCEMIC SULFONYLUREA/
Jones, L.M., et al. Veterinary Pharmacology & Therapeutics. 4th ed. Ames: Iowa State University Press, 1977., p. 704
For more Drug Warnings (Complete) data for CHLORPROPAMIDE (18 total), please visit the HSDB record page.
For treatment of NIDDM in conjunction with diet and exercise.
Chlorpropamide, a second-generation sulfonylurea antidiabetic agent, is used with diet to lower blood glucose levels in patients with diabetes mellitus type II. Chlorpropamide is twice as potent as the related second-generation agent glipizide.
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BB - Sulfonylureas
A10BB02 - Chlorpropamide
Absorption
Readily absorbed from the GI tract. Peak plasma concentrations occur within 2-4 hours and the onset of action occurs within one hour. The maximal effect of chlorpropamide is seen 3-6 hours following oral administration.
Route of Elimination
80-90% of a single oral dose is excreted in the urine as unchaged drug and metabolites within 96 hours.
...EFFECTIVELY ABSORBED FROM GI TRACT ...
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1508
Excreted (percentage)...60 /from table/
Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 722
... 20% excreted unchanged; ... /from table/
Young, L.Y., M.A. Koda-Kimble (eds.). Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Vancouver, WA., Applied Therapeutics, Inc. 1995., p. 48-37
Chlorpropamide is readily absorbed from the GI tract following oral administration. Following oral administration of a single dose, the drug is detectable in plasma within 1 hour and peak plasma chlorpropamide concentrations occur within 2-4 hours.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 1999. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1999 (Plus Supplements)., p. 2732
For more Absorption, Distribution and Excretion (Complete) data for CHLORPROPAMIDE (6 total), please visit the HSDB record page.
Up to 80% of dose is metabolized likely through the liver to to 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA); CBSA may be produced by decomposition in urine. It is unknown whether chlorpropamide metabolites exert hypoglycemic effects.
...METABOLISM OF CHLORPROPAMIDE IS INCOMPLETE, AND ABOUT 20% OF THE DRUG IS EXCRETED UNCHANGED
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1509
...SOME HYDROLYTIC BREAKDOWN OF ACTUAL UREA MOIETY HAS BEEN DETECTED, RESULTING IN FORMATION OF SULFONAMIDE DERIV... RECENT EVIDENCE SUGGESTS THIS...TO BE ARTIFACTUAL & NOT A GENUINE METABOLITE...
Testa, B. and P. Jenner. Drug Metabolism: Chemical & Biochemical Aspects. New York: Marcel Dekker, Inc., 1976., p. 145
FOLLOWING PER ORAL ADMIN TO MAN OF TRITIATED CHLORPROPAMIDE...80% OF DOSE WAS EXCRETED...DURING 7-DAY PERIOD. METABOLITES...WERE P-CHLOROBENZENESULFONAMIDE...[(P-CHLOROPHENYL)SULFONYL]UREA... 1-[(P-CHLOROPHENYL)SULFONYL]-3-(2-HYDROXYPROPYL)UREA. ..&.1-[(P-CHLOROPHENYL)SULFONYL]-3-(3-HYDROXYPROPYL)UREA...
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 558
...DIABETIC PT WERE ADMIN.../CHLORPROPAMIDE/... AT...250-500 MG...PRODUCTS EXCRETED...INCL.../(P-CHLOROPHENYL)SULFONYLUREA/ (21%)... /P-CHLOROBENZENESULFONAMIDE/ (2%), 2-HYDROXYCHLORPROPAMIDE (55%), & 3-HYDROXYCHLORPROPAMIDE (2%).
The Chemical Society. Foreign Compound Metabolism in Mammals Volume 3. London: The Chemical Society, 1975., p. 305
For more Metabolism/Metabolites (Complete) data for CHLORPROPAMIDE (6 total), please visit the HSDB record page.
Chlorpropamide has known human metabolites that include 2-hydroxy-chlorpropamide, 3-hydroxy-chlorpropamide, and p-Chlorobenzene sulfonylurea.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Approximately 36 hours with interindividual variation ranging from 25-60 hours. Duration of effect persists for at least 24 hours.
Chlorpropamid has a long half-life (24 to 48 hours).
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1509
Half-life...24-48 /hours/ /from table/
Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 722
Sulfonylureas such as chlorpropamide bind to ATP-sensitive potassium channels on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
...ACTION OF SULFONYLUREAS APPEARS TO BE STIMULATION OF RELEASE OF INSULIN FROM BETA CELLS. ...TO BE EFFECTIVE, PT MUST HAVE SOME FUNCTIONAL ISLET CELLS... /HYPOGLYCEMIC SULFONYLUREAS/
Jones, L.M., et al. Veterinary Pharmacology & Therapeutics. 4th ed. Ames: Iowa State University Press, 1977., p. 704
Sulfonylureas cause hypoglycemia by stimulating insulin release from pancreatic beta cells. Their effects in the treatment of diabetes ... are more complex. /Sulfonylureas/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1507
Sulfonylureas are now...thought to act by a number of different mechanisms. 1. ...produce a depolarization of the pancreatic islet beta cell membrane potassium ion permeability. This results in a release of preformed insulin into the circulation and occurs mostly in non-insulin dependent diabetics. 2. ...reduce basal glucose output from the liver... 3. increase insulin receptor binding... 4. ...increasing intracellular levels of AMP... 5. increase insulin secretion by suppressing the release of glucagon and somatostatin from alpha and delta pancreatic cells. /Sulfonylureas/
Ellenhorn, M.J., S. Schonwald, G. Ordog, J. Wasserberger. Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning. 2nd ed. Baltimore, MD: Williams and Wilkins, 1997., p. 723
Sulfonylureas lower blood glucose in NIDDM by directly stimulating the acute release of insulin from functioning beta cells of pancreatic islet tissue by an unknown process that involves a sulfonylurea receptor on the beta cell. Sulfonylureas inhibit the ATP potassium channels on the beta cell membrane and potassium efflux, which results in depolarization and calcium influx, calcium-calmodulin binding, kinase activation, and release of insulin containing granules by exocytosis, an effect similar to that of glucose. Insulin is a hormone that lowers blood glucose and controls the storage and metabolism of carbohydrates, proteins, and fats. Therefore, sulfonylureas are effective only in patients whose pancreata are capable of producing insulin. /Sulfonylurea antidiabetic agents/
USP. Convention. USPDI - Drug Information for the Health Care Professional. 19th ed. Volume I.Micromedex, Inc. Englewood, CO., 1999. Content Prepared by the U.S. Pharmacopieal Convention, Inc., p. 284
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Jai Radhe Sales
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Direct Compression
Disintegrants & Superdisintegrants
Lubricants & Glidants
Thickeners and Stabilizers
Granulation
Co-Processed Excipients
Taste Masking
Chewable & Orodispersible Aids
Controlled & Modified Release
Coating Systems & Additives
Emulsifying Agents
Rheology Modifiers
Topical
Surfactant & Foaming Agents
Film Formers & Plasticizers
API Stability Enhancers
Global Sales Information
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
